SRF Ltd. — Capital/Financing Update 2026

Jan 20, 2026

The Corporate Relationship Department, BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P.J. Towers Dalal Street, Mumbai 400 001 Scrip Code- 503806

National Stock Exchange of India Limited “Exchange Plaza” Bandra-Kurla Complex Bandra (E) Mumbai 400 051

Scrip Code-SRF

SRF/SEC/BSE/NSE

20.01.2026

Dear Sir/Madam,

Subject: Capital Expenditure proposal approved by the Board

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held today i.e. January 20, 2026 has approved project for setting up New Pharma Intermediate Plant (PIP-2) for undertaking precursor processes for production of Pharma products at a projected cost of Rs. 180 Crores at Dahej, Gujarat.

Information as required under the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as under:

Disclosure Requirements) Regula	tions, 2015 is as under:
itin it	Nt Alibl
a) exsg capacy	o ppcae
b) existing capacity utilization	Not Applicable
c) proposed capacity addition	Not Applicable
d) period within which theroosed caacit is to be	September 30, 2026
pp pyadded
e) investment required	Rs. 180 Crores
f) mode of financing	Mix of debt and internal accruals
g) rationale	To tap new and upcoming business opportunities in the pharmaspace

Thanking You,

Yours Faithfully,

For SRF LIMITED

RAJAT Digitally signed by RAJAT LAKHANPAL LAKHANPAL Date: 2026.01.20 15:24:00 +05'30'

RAJAT LAKHANPAL Sr. VP (CORPORATE COMPLIANCE) & COMPANY SECRETARY